Literature DB >> 9028744

Recognition and optimum treatment of brucellosis.

J Solera1, E Martínez-Alfaro, A Espinosa.   

Abstract

Brucellosis (infection with Brucella spp.) is a common zoonosis in many parts of the world. Human brucellosis is a multisystem disease that may present with a broad spectrum of clinical manifestations. Treatment of brucellosis must effectively control acute illness and prevent complications and relapse. The choice of regimen and duration of antimicrobial therapy should be based on the presence of focal disease and underlying conditions which contraindicate certain specific antibiotics. The regimen of first choice is combination therapy with doxycycline for 45 days and streptomycin for 14 days. Gentamicin or netilmicin for the first 7 days may be substituted for streptomycin. Second-choice regimens consist of combinations of doxycycline and rifampicin (rifampin) for 45 days, or monotherapy with doxycycline for 45 days. Surgery should be considered for patients with endocarditis, cerebral or epidural abscess, spleen abscess or other abscesses which are antibiotic-resistant. Tetracyclines are generally contraindicated for pregnant patients and children < 8 years old. Rifampicin 900 mg once daily for 6 weeks is considered the drug of choice for treating brucellosis in pregnant women. In children < 8 years old the preferred regimen is rifampicin with cotrimoxazole (trimethoprim-sulfamethoxazole) for 45 days. An alternative regimen consists of a combination of rifampicin for 45 days with gentamicin 5 to 6 mg/kg/day for the first 5 days.

Entities:  

Mesh:

Year:  1997        PMID: 9028744     DOI: 10.2165/00003495-199753020-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  84 in total

Review 1.  Brucella endocarditis: the role of combined medical and surgical treatment.

Authors:  F Jacobs; D Abramowicz; P Vereerstraeten; J L Le Clerc; F Zech; J P Thys
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Comparative study of two regimens in the treatment of brucellosis.

Authors:  M Rodriguez Zapata; A Gamo Herranz; J De La Morena Fernández
Journal:  Chemioterapia       Date:  1987-06

Review 3.  Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Part I. Clinical features and therapy.

Authors:  T M Buchanan; L C Faber; R A Feldman
Journal:  Medicine (Baltimore)       Date:  1974-11       Impact factor: 1.889

4.  Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study.

Authors:  G Acocella; A Bertrand; J Beytout; J B Durrande; J A Garcia Rodriguez; J Kosmidis; M Micoud; M Rey; M Rodriguez Zapata; J Roux
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

5.  Antibacterial activity of lomefloxacin against Brucella melitensis.

Authors:  S M Qadri; S al-Sedairy; Y Ueno
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

6.  Brucellosis outbreak attributed to ingestion of umpasteurized goat cheese.

Authors:  E J Young; U Suvannoparrat
Journal:  Arch Intern Med       Date:  1975-02

7.  Treatment of human brucellosis with netilmicin and doxycycline.

Authors:  J Solera; A Espinosa; P Geijo; E Martínez-Alfaro; L Sáez; M A Sepúlveda; M D Ruiz-Ribó
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

8.  Neurobrucellosis: clinical and therapeutic features.

Authors:  D R McLean; N Russell; M Y Khan
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

9.  Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice.

Authors:  S Domingo; I Gastearena; A I Vitas; I López-Goñi; C Dios-Viéitez; R Díaz; C Gamazo
Journal:  J Antimicrob Chemother       Date:  1995-10       Impact factor: 5.790

10.  Microangiopathic hemolytic anemia and severe thrombocytopenia in Brucella infection.

Authors:  A Di Mario; S Sica; G Zini; P Salutari; G Leone
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

View more
  45 in total

Review 1.  Detection of Brucellae in blood cultures.

Authors:  P Yagupsky
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 2.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Evaluation of conventional castaneda and lysis centrifugation blood culture techniques for diagnosis of human brucellosis.

Authors:  Basappa G Mantur; Smita S Mangalgi
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

4.  A case of brucellar septic arthritis of the knee with a prolonged clinical course.

Authors:  Ergin Ayaşlioğlu; Ozlem Ozlük; Dilek Kiliç; Sedat Kaygusuz; Simay Kara; Gülümser Aydin; Fügen Cokca; Emin Tekeli
Journal:  Rheumatol Int       Date:  2004-03-06       Impact factor: 2.631

5.  Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study.

Authors:  Hakan Erdem; Aysegül Ulu-Kilic; Selim Kilic; Mustafa Karahocagil; Ghaydaa Shehata; Necla Eren-Tulek; Funda Yetkin; Mustafa Kemal Celen; Nurgul Ceran; Hanefi Cem Gul; Gurkan Mert; Suda Tekin-Koruk; Murat Dizbay; Ayse Seza Inal; Saygin Nayman-Alpat; Mile Bosilkovski; Dilara Inan; Nese Saltoglu; Laila Abdel-Baky; Maria Teresa Adeva-Bartolome; Bahadir Ceylan; Suzan Sacar; Vedat Turhan; Emel Yilmaz; Nazif Elaldi; Zeliha Kocak-Tufan; Kenan Ugurlu; Basak Dokuzoguz; Hava Yilmaz; Sibel Gundes; Rahmet Guner; Nail Ozgunes; Asim Ulcay; Serhat Unal; Saim Dayan; Levent Gorenek; Ahmet Karakas; Yesim Tasova; Gaye Usluer; Yasar Bayindir; Behice Kurtaran; Oguz Resat Sipahi; Hakan Leblebicioglu
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

6.  Brucella, a bacterium with multiple ways of causing infection.

Authors:  Alejandro Perez; Mezgebe Berhe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-26

7.  Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.

Authors:  M C Lecaroz; M J Blanco-Prieto; M A Campanero; H Salman; C Gamazo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

8.  The genome sequence of the facultative intracellular pathogen Brucella melitensis.

Authors:  Vito G DelVecchio; Vinayak Kapatral; Rajendra J Redkar; Guy Patra; Cesar Mujer; Tamara Los; Natalia Ivanova; Iain Anderson; Anamitra Bhattacharyya; Athanasios Lykidis; Gary Reznik; Lynn Jablonski; Niels Larsen; Mark D'Souza; Axel Bernal; Mikhail Mazur; Eugene Goltsman; Eugene Selkov; Philip H Elzer; Sue Hagius; David O'Callaghan; Jean-Jacques Letesson; Robert Haselkorn; Nikos Kyrpides; Ross Overbeek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

9.  Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Hugo Lana; Miguel Ángel Campanero; David Salas; Ana Gloria Gil; Elisa Elizondo; Nora Ventosa; Jaume Veciana; María J Blanco-Prieto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

10.  Multicenter study of brucellosis in Egypt.

Authors:  Hassan Samaha; Meshref Al-Rowaily; Ramadan M Khoudair; Hossam M Ashour
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.